Introducing
Prof Tomas Kalincik
Hello, I’m Tomas, Head of the Clinical Outcomes Research (CORe) Unit.

a little bit about me
I am the Head of the CORe Unit at the University of Melbourne, as well as the Head of the Multiple Sclerosis and Neuroimmunology Service at the Royal Melbourne Hospital.
Together with the CORe team, I specialise in analytics of observational data in neurology. I am an active participant in the global MSBase collaboration, undertaking a role in the MSBase Scientific Leadership Group.
My research interests revolve around disease outcomes in multiple sclerosis and Neuromyelitis Optica. These comprise comparative treatment effectiveness, management of treatment failure, individual treatment response, personalised therapy, prognostics, epidemiology and utility of volumetric MRI.
Publications
- Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis.
- Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis
- Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis
- Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis
- Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis
- Prognostic value of acute cerebrospinal fluid abnormalities in antibody-positive autoimmune encephalitis
- Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium.
- Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium
- Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium
- Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium
- Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium
- Peripheral Immune Cell Ratios and Clinical Outcomes in Seropositive Autoimmune Encephalitis: A Study by the Australian Autoimmune Encephalitis Consortium
- Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS.
- Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
- Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
- Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
- Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
- Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS
- Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study.
- Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study
- Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study
- Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study
- Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study
- Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study
- Determinants of therapeutic lag in multiple sclerosis.
- Determinants of therapeutic lag in multiple sclerosis
- Determinants of therapeutic lag in multiple sclerosis
- Determinants of therapeutic lag in multiple sclerosis
- Determinants of therapeutic lag in multiple sclerosis
- Determinants of therapeutic lag in multiple sclerosis
- Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
- Adverse events related to antiepileptic drugs.
- Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
- Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
- Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
- Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
- Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
- Adverse events related to antiepileptic drugs
- Adverse events related to antiepileptic drugs
- Adverse events related to antiepileptic drugs
- Adverse events related to antiepileptic drugs
- Adverse events related to antiepileptic drugs
- Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic.
- Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic
- Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic
- Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic
- Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic
- Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic
- A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia.
- A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia